2024 AUA preview: Dr. Elterman on key research in BPH
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Investigators found the greatest prevalence of chronic kidney disease among patients with the highest serum urate levels.
Researchers describe feasibility and acceptability results of a quality improvement project aimed at increasing referrals to exercise for patients undergoing cancer treatment. A clinical workflow…
In this interview, Mary-Ellen Taplin, MD, discusses disparities in prostate cancer care and a unique initiative aiming to alleviate those disparities.
Ruchika Talwar hosts Yash Shah and Mihir Shah, a urologist from Jefferson in Philadelphia. They delve into their innovative research on the Utility of Artificial…
“Along those lines, we’ve taken away the traditional step therapy that has dictated overactive bladder care for quite some time,” says Ariana L. Smith, MD,…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
FDA approval of the APOL1-targeting treatment inaxaplin is highly anticipated.
bladder cancer (BC), neoadjuvant chemotherapy after radical cystectomy (RC), gemcitabine/cisplatin, MVAC/dose-dense MVAC, gemcitabine/carboplatin, circulating tumor DNA.
“Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk…
“In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II…